CN103169548A - Drug-carrying type artificial lens capable of being opened by laser - Google Patents
Drug-carrying type artificial lens capable of being opened by laser Download PDFInfo
- Publication number
- CN103169548A CN103169548A CN2013100421862A CN201310042186A CN103169548A CN 103169548 A CN103169548 A CN 103169548A CN 2013100421862 A CN2013100421862 A CN 2013100421862A CN 201310042186 A CN201310042186 A CN 201310042186A CN 103169548 A CN103169548 A CN 103169548A
- Authority
- CN
- China
- Prior art keywords
- laser
- drug
- artificial lens
- opened
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention discloses a drug-carrying type artificial lens capable of being opened by a laser. The drug-carrying type artificial lens capable of being opened by the laser comprises an artificial lens main body, a plurality of drug storing holes with preset intervals are formed in the peripheral surface of the artificial lens main body, and micro-capsules loading active drug and capable of being punched through or resolved by the laser are embedded in the drug-storing holes. A plurality of drug micro-capsules are embedded into the peripheral portion of the artificial lens, the lens is opened to release by the laser on a suitable opportunity to achieve a treatment goal, and relative to a drug sustained releasing system, side effects brought by long-term sustained drug releasing is avoided. Besides the treatment goal of post-operation inflammatory resistance and posterior capsule opacification resistance, the drug-carrying type artificial lens capable of being opened by the laser can be embedded to achieve the purpose of controlling eye diseases aiming at certain diseases of age related macular degeneration, diabetic retinopathy and the like together with the complication of a cataract, and the complications caused by multiple injections of a vitreous cavity and the side effects of systemic administration are avoided or reduced.
Description
Technical field
The present invention relates to artificial intraocular lenses's technical field, but the medicine carried artificial lens that especially a kind of laser is opened.
Background technology
At present the research of the subsidiary drug release device of artificial intraocular lenses mostly is zoopery, interested medicine mostly is anti-inflammatory drug, and the content of research is mainly to control Postoperative inflammatory reaction and inhibition or delay posterior capsule opacification to form.Few for the correlational study that loads back segment Drug therapy eye posterior segment disease, having research report tension link slow-released system to load bevacizumab (avastin) implants and can detect respective concentration at each position of eyeball, but only as the effectiveness of checking slow-released system, do not have in conjunction with clinical efficacy.Therefore can design zoopery or the clinical trial of being correlated with and attach the medicament slow release device to effectiveness and the feasibility of the treatment of eye posterior segment disease with the checking artificial intraocular lenses.
Along with social development, cataract operation and artificial intraocular lenses's implantation is increasingly general.The care method of postoperative routine is hormone and non-hormone anti-inflammatory agent eye dripping, and it nurses loaded down with trivial details and easy infection.For saving the inconvenience of routine care after operation in patients, reduce infection chance, implant artificial intraocular lenses or the tension link that is accompanied with drug delivery system in operation, make to discharge medicine in its a period of time after surgery and reach and control inflammation or prevent that posterior capsule opacification from having been reported.Existing slow-released system adopts Biodegradable material, namely begins to discharge medicine after implanting ophthalmic, discharging near 0 grade of kinetics, can not the manual control drug release, and the medicines such as long-term releasing hormone easily cause side effect and other complication.
patent announcement number is 202078423U, patent name is that the utility model patent of artificial crystal for slow-releasing medicines discloses and a kind ofly has the hole on the extended connection loop of artificial intraocular lenses's eyeglass end, be filled with medicinal slow release agent in the hole, be provided with the anti-inflammatory agent polymer coating connecting the loop surface, the time of medicament slow release is 30 days to 150 days, this structure can be called a kind of " slow-released system ", just begin the long-time medicine that slowly discharges after namely implanting ophthalmic, there is following weak point in this release structures: (1) the sustained release medicine within the quite a while of packing into after ophthalmic, easily cause complication.(2) pack that slow-released system just comes into operation after ophthalmic into, can't manual control release time, treatment motility and specific aim are lower.
Summary of the invention
The object of the invention is to overcome the long-time medicine that slowly discharges of artificial intraocular lenses's medicament slow release structure in prior art, easily cause complication, can not control the technical problem of release time, but a kind of medicine carried artificial lens of laser unlatching of energy abrupt release medicine is provided.
For realizing above purpose, the present invention has taked following technical scheme: but the medicine carried artificial lens that laser is opened, comprise artificial intraocular lenses's main body, have a plurality of drug storage holes that maintain respectively preset space length on the periphery surface of artificial intraocular lenses's main body, the drug storage hole is embedded in loads active medicine, and the microcapsule that can be punched or decompose by laser.The material of microcapsule is silicone-hydrogel material or polyphosphazene polymer esters biomaterial.
The reason that the present invention is chosen in the perforate of artificial intraocular lenses's body peripheral edge is to expose easily under mydriasis that (old people's pupil is less, iris adjusting power is low, connecting loop during mydriasis is difficult for exposing), utilize laser (or photosensitizer) to open, treatment has more specific aim, the complication of having avoided the long-term releasing hormone class of slow-released system medicine etc. to cause.Damage is also less simultaneously.
Patent application of the present invention is not add sustained-release matrix with general drug release device difference, by the laser open opening device, the release of manual control medicine, abrupt release rather than long-term release after opening, make treatment have more specific aim, the complication of having avoided delayed release device sustained release medicine to cause.For making medicine reach treatment concentration, can not adopt carrier matrix, directly medicine is squeezed into microcapsule with syringe, or select decomposition rate carrier matrix faster, drug release rate is larger, relatively large drug release was arranged in the short time, just can increase in theory disperse to the drug level of each one of eyeball, to reach better therapeutic effect.Repeatedly opening device discharges medicine, and its effect is similar to repeatedly carries out intravitreal injection, but the complication that can avoid the latter to produce.
The microcapsule that is used for the coating active medicine can be various shape, is preferably elliposoidal or spherical.Cyst membrane can be made anterior thicker, the close thinner form of posterior lens capsule membranous part, make it both to have certain degree of hardness, be unlikely to come off after laser is punched, the thinner laser operations of also being convenient to of simultaneously rear utmost point section.
The present invention compared with prior art, has following advantage: embed many medicament microcapsules at artificial intraocular lenses's periphery, machine is opened with laser and is discharged medicine and reach therapeutic purposes in due course, drug sustained release system relatively, the side effect of having avoided long-term sustained release medicine to bring.The purpose for the treatment of is except the anti-posterior capsule opacification of postoperative antiinflammatory, to some disease such as age related maculopathy, diabetic retinopathy etc., if be associated with simultaneously cataract, implantable this kind artificial intraocular lenses reaches the purpose of controlling ocular disease, avoids or reduces the complication of vitreous chamber multiple injection and the side effect of systemic administration.
Description of drawings
Fig. 1 is for being the front view that is mounted with artificial intraocular lenses's main body of medicament microcapsule;
Fig. 2 is artificial intraocular lenses's main body section view of being mounted with medicament microcapsule (arrow represent the optical axis position);
Fig. 3 is embodiment two schematic diagrams.
The specific embodiment
Below in conjunction with the drawings and specific embodiments, content of the present invention is described in further details.
Embodiment one:
See also illustrated in figures 1 and 2, but the medicine carried artificial lens that laser is opened, comprise artificial intraocular lenses's main body 1, the artificial intraocular lenses is the soft Foldable type artificial intraocular lenses of standard, as hydrogel or silica gel material, also can be other materials such as acrylate etc., have a plurality of drug storage holes that maintain respectively preset space length 2 on the periphery surface of artificial intraocular lenses's main body 1, drug storage hole 2 is embedded in the microcapsule 3 that loads active medicine, also can be punched by laser or decompose, and the material of microcapsule 3 is silicone-hydrogel material or polyphosphazene polymer esters biomaterial.The diameter of artificial intraocular lenses's main body mostly is 5.5-6.0mm, occupies the part periphery because establishing drug storage hole and medicament microcapsule, can consider artificial intraocular lenses's main diameter is increased to 6.5mm, also can not increase, and by the periphery place, does not affect the daily life needs because of hole, drug storage hole and microcapsule.
In the present embodiment, microcapsule 3 is shaped as spherical or elliposoidal.
The peripheral drug storage of artificial intraocular lenses's main body 1 hole 2 visual specific purposes of quantity and becoming, drug storage hole 2 is 3-5.
But the material that microcapsule 3 materials that are used for the coating active medicine are opened or decomposed for laser as silicone-hydrogel, polyphosphazene polymer esters material, and can add label, as color or sign flag, is convenient to laser positioning.Above-mentioned material should be nontoxic, and good biocompatibility is arranged.
The active medicine that loads in microcapsule 3 can be anti-inflammatory drug, as dexamethasone (triamcinolone acetonide), diclofenac, indomethacin etc.The active medicine of filling in aperture can be anti-angiogenic endothelial growth hormone, as bevacizumab (avastin), Lucentis (lucentis) etc.The active medicine of filling in aperture can be antibiotic, antifungal agent, antiviral agents, immunosuppressant, and imagination at a specified future date comprises biological peptide class and gene therapy.The active medicine that loads in microcapsule 3 can not filled carrier matrix, and some drugs also can be filled carrier matrix because character is unstable.The carrier matrix of filling in drug release device can be biodegradable material, as PLGA, PVA, PLA, PVA, HPMC etc.Have been reported by one or more material different proportions and be mixed to get different molecular weight or density, then obtain different drug release rates.Preferred rate of release is pharmaceutical carrier substrate faster.Some drugs such as avastin, lucentis belong to monoclonal antibody, all need cryopreservation for keeping its activity.After implanting ophthalmic, can keep its biological activity for a long time under body temperature be the problem that needs are considered.Can be resolved by zoopery.
Artificial intraocular lenses in the present embodiment can punch or decompose the microcapsule shell after implanting ophthalmic as required with laser, discharge medicine and reach therapeutic purposes.The inconvenience of disease or postoperative care has been saved in this design, relative drug sustained release system, the side effect of having avoided long-term release medicine to bring.
Embodiment two:
See also shown in Figure 3ly, the present embodiment is different from embodiment one to be, drug storage hole 2 does not penetrate the cylindrical tunnel of artificial intraocular lenses's main body 1, but is a shrinkage pool.
Above-listed detailed description is that this embodiment limits the scope of the claims of the present invention for the illustrating of possible embodiments of the present invention, and the equivalence that all the present invention of disengaging do is implemented or change, all should be contained in the scope of the claims of this case.
Claims (7)
1. but the medicine carried artificial lens opened of laser, comprise artificial intraocular lenses's main body (1), it is characterized in that: have a plurality of drug storage holes (2) that maintain respectively preset space length on the periphery surface of artificial intraocular lenses's main body (1), drug storage hole (2) is embedded in the microcapsule (3) that loads active medicine, also can be punched by laser or decompose.
2. but the medicine carried artificial lens opened of laser as claimed in claim 1, it is characterized in that: the material of described microcapsule (3) is silicone-hydrogel material or polyphosphazene polymer esters biomaterial.
3. but the medicine carried artificial lens opened of laser as claimed in claim 1, it is characterized in that: described drug storage hole (2) is located at apart from the 0.2-0.3mm place of artificial intraocular lenses's main body (1) periphery, drug storage hole (2) penetrates artificial intraocular lenses's main body (1), and the diameter in drug storage hole (2) is 0.3-0.5mm.
4. but the medicine carried artificial lens opened of laser as claimed in claim 1 is characterized in that: described microcapsule (3) be shaped as spherical or elliposoidal.
5. but the medicine carried artificial lens opened of laser as claimed in claim 1, it is characterized in that: described drug storage hole (2) is for cylindrical.
6. but the medicine carried artificial lens opened of laser as claimed in claim 1, it is characterized in that: described drug storage hole (2) is 3-5.
7. but the medicine carried artificial lens opened of laser as claimed in claim 1, it is characterized in that: described drug storage hole (2) is shrinkage pool.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100421862A CN103169548A (en) | 2013-02-01 | 2013-02-01 | Drug-carrying type artificial lens capable of being opened by laser |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100421862A CN103169548A (en) | 2013-02-01 | 2013-02-01 | Drug-carrying type artificial lens capable of being opened by laser |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103169548A true CN103169548A (en) | 2013-06-26 |
Family
ID=48630050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100421862A Pending CN103169548A (en) | 2013-02-01 | 2013-02-01 | Drug-carrying type artificial lens capable of being opened by laser |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103169548A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101711445B1 (en) * | 2015-09-23 | 2017-03-02 | 서강대학교 산학협력단 | Manufacturing method of sustained drug release contact lens |
| CN106901871A (en) * | 2015-12-23 | 2017-06-30 | 爱博诺德（北京）医疗科技有限公司 | Intraocular lens with one or more extentions |
| CN109223253A (en) * | 2018-08-16 | 2019-01-18 | 河南科技大学第附属医院 | A kind of breast prosthesis |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2531755Y (en) * | 2002-03-29 | 2003-01-22 | 何伟 | Slow-releasing agent carried artificial lens |
| US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
| US20100226962A1 (en) * | 2009-03-03 | 2010-09-09 | Rodstrom Theron R | Peri-corneal drug delivery device |
| CN102421418A (en) * | 2009-03-09 | 2012-04-18 | 得克萨斯系统大学评议会 | Hollow gold nanospheres (haunss) and haunss-loaded microspheres useful in drug delivery |
| CN202472154U (en) * | 2012-02-14 | 2012-10-03 | 中国人民解放军南京军区南京总医院 | Improved corneal contact lens for treatment |
| CN102805870A (en) * | 2012-05-25 | 2012-12-05 | 天津大学 | Gold nano-spherical shell carrier with procedural gene drug release property and preparation method |
-
2013
- 2013-02-01 CN CN2013100421862A patent/CN103169548A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
| CN2531755Y (en) * | 2002-03-29 | 2003-01-22 | 何伟 | Slow-releasing agent carried artificial lens |
| US20100226962A1 (en) * | 2009-03-03 | 2010-09-09 | Rodstrom Theron R | Peri-corneal drug delivery device |
| CN102421418A (en) * | 2009-03-09 | 2012-04-18 | 得克萨斯系统大学评议会 | Hollow gold nanospheres (haunss) and haunss-loaded microspheres useful in drug delivery |
| CN202472154U (en) * | 2012-02-14 | 2012-10-03 | 中国人民解放军南京军区南京总医院 | Improved corneal contact lens for treatment |
| CN102805870A (en) * | 2012-05-25 | 2012-12-05 | 天津大学 | Gold nano-spherical shell carrier with procedural gene drug release property and preparation method |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101711445B1 (en) * | 2015-09-23 | 2017-03-02 | 서강대학교 산학협력단 | Manufacturing method of sustained drug release contact lens |
| WO2017052263A1 (en) * | 2015-09-23 | 2017-03-30 | 서강대학교 산학협력단 | Method for producing sustained drug-release contact lens |
| CN106901871A (en) * | 2015-12-23 | 2017-06-30 | 爱博诺德（北京）医疗科技有限公司 | Intraocular lens with one or more extentions |
| CN106901871B (en) * | 2015-12-23 | 2021-08-24 | 爱博诺德(北京)医疗科技股份有限公司 | Intraocular lens with one or more additional portions |
| CN109223253A (en) * | 2018-08-16 | 2019-01-18 | 河南科技大学第附属医院 | A kind of breast prosthesis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0863729B1 (en) | Implantable controlled release device to deliver drugs directly to an internal portion of the body | |
| Kaji et al. | Drug delivery devices for retinal diseases | |
| Yasukawa et al. | Drug delivery from ocular implants | |
| Cao et al. | Recent advances in intraocular sustained-release drug delivery devices | |
| Lee et al. | Biodegradable implants for sustained drug release in the eye | |
| Kearns et al. | Drug delivery systems for the eye | |
| US8469934B2 (en) | Pulsatile peri-corneal drug delivery device | |
| AU2014350095B9 (en) | Eye device | |
| CN203220483U (en) | Artificial-crystal drug releasing apparatus capable of opening by laser | |
| JP2003511205A (en) | Eye drop delivery device | |
| CN103393496A (en) | Nasolacrimal drainage system implants for drug therapy | |
| RU2749426C2 (en) | Non-invasive medicine delivery technique using eye inlay | |
| MXPA03011610A (en) | Ophthalmic drug delivery device. | |
| CA2383499A1 (en) | Drug delivery device | |
| JPS6322516A (en) | Controlled release biocorrosive drug administration system | |
| KR20050108345A (en) | Sustained release and method for ocular delivery of carbonic anhydrase inhibitors | |
| US20210322212A1 (en) | Implantable intraocular drug delivery devices | |
| A Peptu et al. | Modern drug delivery systems for targeting the posterior segment of the eye | |
| Rupenthal | Drug-device combination approaches for delivery to the eye | |
| CN103169548A (en) | Drug-carrying type artificial lens capable of being opened by laser | |
| CN110337296A (en) | Intraocular drug delivery device and correlation technique | |
| Nagaraj et al. | A review on recent advancements in ophthalmology devices: currently in market and under clinical trials | |
| WO2018143481A1 (en) | Sustained drug release device that can be reinjected with the drug, and injectable gel for refilling | |
| Lim et al. | Surgical management of late dislocated lens capsular bag with intraocular lens and endocapsular tension ring | |
| US10463532B2 (en) | Method for placing implant in choroid that can less invasively and simply place implant in choroid in optic disc-macula area |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130626 |